Gilead Sciences Shanghai Pharmaceutical Technology Co. Ltd.

To evaluate the efficacy and safety of liposomal amphotericin B for injection (trademark: Amphotericin B®) in Chinese adults and pediatric patients aged 1 month to 18 years.

Objective 1: To record the number of people who use PrEP once a day among 3,200 high-risk MSM and college-age youth in two Chinese cities. Objective 2: To obtain HIV/STI risk behaviors and knowledge, perceptions, and practices regarding sexual behaviors and PrEP use through questionnaire surveys among 3,200 high-risk MSM and college-age youth in two Chinese cities. Objective 3: To obtain data on syphilis and HIV prevalence among 3,200 MSM and college-age youth and syphilis, gonorrhea, chlamydia, and HIV prevalence among 1,200 PrEP users in two Chinese cities. Objective 4: To determine retention, adherence, and characteristics of 1,200 PrEP users at 6 and 12 months. Objective 5: To evaluate the experience of the PrEP WeChat mini-program intervention among MSM and college-age youth through in-depth interviews with selected participants (n = 30).

To assess the effectiveness, safety, adherence, resource utilization, and patient health status during treatment with B/F/TAF in routine clinical care.